Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir

Current Drug Delivery

Volumn 8, Issue 4, 2011, Pages 392-397

  Boonyapiwat, Boontarika ^a   Sarisuta, Narong ^b   Kunastitchai, Sarinnate ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Absorption; Caco 2 cells; Characterization; Drug transport; Liposomes; Zanamivir

Indexed keywords

CHOLESTEROL; LIPOSOME; OSELTAMIVIR; PHOSPHATIDYLCHOLINE; ZANAMIVIR;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUTION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; LIPOSOMAL DELIVERY; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL;

BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; HUMANS; INTESTINAL ABSORPTION; INTESTINES; LIPOSOMES; PERMEABILITY; ZANAMIVIR;

EID: 79959334732     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720111795767915     Document Type: Article

References (28)

1. Kiso, M.; Mitamura, K.; Sakai-Tagawa, Y.; Shiraishi, K.; Kawakami, C.; Kimura, K.; Hayden, F.G.; Sugaya, N.; Kawaoka, Y. Resistant influenza A viruses in children treated with osel-tamivir: descriptive study. Lancet, 2004, 64, 759-765.
2. Kaiser, L.; Wat, C.; Mills, T.; Mahoney, P.; Ward, P.; Hayden, F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med., 2003, 163(14), 1667-1672.
3. Nicholson, K.G.; Aoki, F.Y.; Osterhaus, A.D.; Trottier, S.; Carewicz, O.; Mercier, C.H.; Rode, A.; Kinnersley, N.; Ward, P. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet, 2000, 355(9218), 1845-1850.
4. Nordstrom, B.L.; Sung, I.; Suter, P.; Szneke, P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr. Med. Res. Opin., 2005, 21(5), 761-768.
5. Moscona, A. Oseltamivir resistance-disabling our influenza de-fenses. N. Engl. J. Med., 2005, 353(25), 2633-2636.
6. Le, Q.M.; Kiso, M.; Someya, K.; Sakai, Y.T.; Nguyen, T.H.; Nguyen, K.H.; Pham, N.D.; Ngyen, H.H.; Yamada, S.; Muramoto, Y.; Horimoto, T.; Takada, A.; Goto, H.; Suzuki, T.; Suzuki, Y.; Kawaoka, Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature, 2005, 438(7069), 754.
7. Jong, M.D.D.; Tran, T.T.; Truong, H.K.; Vo, M.H.; Smith, G.J.; Nguyen, V.C.; Bach, V.C.; Phan, T.Q.; Do, Q.H.; Guan, Y.; Peiris, J.S.; Tran, T.H.; Farrar, J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med., 2005, 353, 2667-2672.
8. Gupta, R.K.; Nguyen-Van-Tam, J.S.; Jong, M.D.D.; Hien, T.T.; Farrar, J. Oseltamivir resistance in influenza A (H5N1) infection. N. Engl. J. Med., 2006, 354, 1423-1424.
9. Escuret, V.; Frobert, E.; Bouscambert-Duchamp, M.; Sabatier, M.; Grog, I.; Valette, M.; Lina, B.; Morfin, F.; Ferraris, O. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J. Clin. Virol., 2008, 41, 25-28.
10. Cass, L.M.; Efthymiopoulos, C.; Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet., 1999, 36, 1-11.
11. Moscona, A. Neuraminidase inhibitors for influenza. N. Engl. J. Med., 2005, 353, 1363-1373.
12. Stubbs, R.J.; Harker, A.J. Automated high-performance liquid chromatographic method for the determination of a neuraminidase inhibitor (GG167) in human serum by pre-column fluorescence de-rivatisation using benzoin. J. Chromatogr. B., 1995, 670, 279-285.
13. Beigel, J.H.; Farrar, J.; Han, A.M.; Hayden, F.G.; Hyer, R.; Jong, M.D.; Lochindarat, S.; Nguyen, T.K.; Nguyen, T.H.; Tran, T.H.; Nicoll, A.; Touch, S.; Yuen, K.Y. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5 (2005). Current concepts: Avian influenza A (H5N1) infections in Humans. N. Engl. J. Med., 2005, 353, 1374-1385.
14. Riel, V.D.; Munster, V.J.; Wit, D.E.; Rimmelzwaan, G.F.; Fouchier, R.A.; Osterhaus, A.D.; Kuiken, T. H5N1 virus attachment to lower respiratory tract. Science, 2006, 312, 399.
15. Uiprasertkul, M.; Puthavathana, P.; Sangsiriwut, K.; Pooruk, P.; Srisook, K.; Peiris, M.; Nicholls, J.M.; Chokephaibulkit, K.; Van-prapar, N.; Auewarakul, P. Influenza A H5N1 replication sites in humans. Emerg. Infect. Dis., 2005, 11, 1036-1041.
16. Peng, A.W.; Milleri, S.; Stein, D.S. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob. Agents Chemother., 2000, 44, 1974-1976.
17. Teshima, M.; Kawakami, S.; Fumoto, S.; Nishida, K.; Nakamura, J.; Nakashima, M.; Nakagawa, H.; Ichikawa, N.; Sasaki, H. PEGy-lated liposomes loading palmitoyl prednisolone for prolonged blood concentration of prednisolone. Biol. Pharmaceut. Bull., 2006, 29, 1436-1440.
18. Brocks, D.R.; Betageri, G.V. Enhanced oral absorption of halofan-trine enantiomers after encapsulation in a proliposomal formulation. J. Pharm. Pharmacol., 2002, 54, 1049-1053.
19. Chandler, M.; Bamford, M.J.; Conroy, R.; Lamont, B.; Patel, B.; Patel, V.K.; Steeples, I.P.; Storer, R.; Weir, N.G.; Wright, M.; Williamson, C. Synthesis of the potent influenza neuraminidase inhibitor 4-guanidino Neu5Ac2en. X-Ray molecular structure of 5-acetamido-4-amido-2,6-anhydro-3-4,5-trideoxy-D-erythro-L-gluco-nononic acid. J. Chem. Soc. Perkin. Trans., 1995, 1, 1173-1180.
20. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65, 55-63.
21. Liu, Z.Y.; Wang, B.; Zhao, L.; Li, Y.; Shao, H.; Yi, H.; You, X.; Li, Z. Synthesis and anti-influenza activities of carboxyl alkoxyal-kyl esters of 4-guanidino-Neu5Ac2en (zanamivir). Bioorg. Med. Chem. Lett., 2007, 17, 4851-4854.
22. Obata, K.; Sugano, K.; Saitoh, R.; Higashida, A.; Nabuchi, Y.; Machida, M.; Aso, Y. Prediction of oral drug absorption in humans by theoretical passive absorption model. Int. J. Pharm., 2005, 293, 183-192.
23. Camenisch, G.; Waterbeemd V.D.F.H. Shapes of membrane per-meability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. Eur. J. Pharm. Sci., 1998, 6, 321-329.
24. Zou, W.; Sun, W.; Zhang, N.; Xu, W. Enhanced Oral Bioavaila-bility and Absorption Mechanism Study of N3-O-Toluyl-Fluorouracil-Loaded Liposomes. J. Biomed. Nanotechnol., 2008, 4(1), 90-98.
25. Harish, P.M.; Nilden, T.S.; Stevenson, R.W. Intracellular digestion of saturated and unsaturated phospholipid liposomes by mucosal cells. Possible mechanism of transport of liposomally entrapped macromolecules across the isolated vascularly perfused rabbit il-eum. Biochim. Biophys. Acta., 1985, 839(1), 40-49.
26. Calvagno, M.G.; Celia, C.; Paolino, D.; Cosco, D.; Iannone, M.; Castelli, F.; Doldo, P.; Frest, M. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes. Curr. Drug Deliv., 2007, 4(1), 89-101.
27. nd ed.; Oxford University Press: Oxford, 2003.
28. Artursson, P.; Karlsson, J.; Ocklind, G.; Schipper, N. Studying transport processes in absorptive epithelia. In: Shaw AJ, Ed.; Oxford Press, New York, 1996; pp. 111-133.